Nuvalent, Inc.

Healthcare · Biotechnology · United States

Last price 123.96 USD (At close: Jul 14, 2026) · Market cap 9.83B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of...